Alterity Therapeutics to Present Positive Disease-Modifying Data for ATH434 in MSA at AAN Meeting

summarizeSummary

This announcement signals further positive validation for Alterity's lead drug candidate, ATH434, in treating Multiple System Atrophy. Presenting a 'disease-modifying signal' at a prestigious event like the AAN Annual Meeting can significantly boost investor confidence and attract attention from the scientific and medical communities. This follows the company's previous disclosure of a KOL event to discuss Phase 2 data and reinforces the positive momentum as Alterity prepares to initiate a pivotal Phase 3 trial for ATH434.

check_boxKey Events

• Late-Breaker Oral Presentation Scheduled

  Dr. Daniel Claassen, Chief Medical Advisor, will deliver an oral presentation at the American Academy of Neurology (AAN) Annual Meeting on April 21, 2026.

• Positive Clinical Data Highlighted

  The presentation will focus on ATH434 demonstrating a 'Disease-Modifying Signal' in Multiple System Atrophy (MSA) using the MuSyCA Composite Scale.

• Reinforces Phase 2 Efficacy

  This presentation further supports the previously reported clinically meaningful efficacy of ATH434 in its randomized, double-blind, placebo-controlled Phase 2 clinical trial in MSA participants.

• Advancing Towards Phase 3

  The company is preparing to initiate a Phase 3 pivotal trial in MSA, building on these positive results.

auto_awesomeAnalysis

This announcement signals further positive validation for Alterity's lead drug candidate, ATH434, in treating Multiple System Atrophy. Presenting a 'disease-modifying signal' at a prestigious event like the AAN Annual Meeting can significantly boost investor confidence and attract attention from the scientific and medical communities. This follows the company's previous disclosure of a KOL event to discuss Phase 2 data and reinforces the positive momentum as Alterity prepares to initiate a pivotal Phase 3 trial for ATH434.